Anticancer drugs: an underestimated risk or an underutilised resource in mutagenesis?
- 30 September 1995
- journal article
- review article
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 331 (1) , 1-26
- https://doi.org/10.1016/0027-5107(95)00063-o
Abstract
No abstract availableKeywords
This publication has 144 references indexed in Scilit:
- Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugsJournal of Molecular Biology, 1994
- Structural basis of the induction of unscheduled DNA synthesis in rat hepatocytesMutagenesis, 1994
- Effect of distamycin on chlorambucil-induced mutagenesis in pZ189: evidence of a role for minor groove alkylation at adenine N-3Mutagenesis, 1994
- Polymerase chain reaction-directed DNA sequencing of bleomycin-induced “nondeletion”-Type, 6-thioguanine-resistant mutants in chinese hamster ovary cell derivative AS52: Effects of an inhibitor and a mimic of superoxide dismutaseEnvironmental and Molecular Mutagenesis, 1994
- Amonafide as first-line chemotherapy for metastatic breast cancerEuropean Journal Of Cancer, 1994
- DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chainJournal of Medicinal Chemistry, 1990
- Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocationGenes, Chromosomes and Cancer, 1990
- DNA polymerase action on bulky deoxyguanosine and deoxyadenosine adductsCarcinogenesis: Integrative Cancer Research, 1990
- Redox chemistry of the 9-anilinoacridine class of antitumor agentsJournal of Medicinal Chemistry, 1987
- Recovery from the ‘Lethal’ Effects of Cross-Linking AlkylationNature, 1965